Two-Field Lymph Node Dissection with Adjuvant Radiation Therapy is Similar to 3-Field Lymph Node Dissection for Patients with Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma

M. N. Liu,X. Fu,X. W. Cai,J. Q. Xiang,Y. W. Zhang,Z. Zhu

DOI: https://doi.org/10.1016/j.ijrobp.2016.06.1069

2016-01-01

Abstract:There have been many controversies about the optimal extent of lymph node dissection for thoracic esophageal cancer. Data from Japan showed the superiority of three-field lymph node dissection (3FLND) with respect to the survival rate. We conducted the study to compare effects between two-field lymph node dissection (2FLND) with adjuvant radiation therapy (2FLND + RT) and 3FLND for T3-4N0-3M0 thoracic esophageal squamous cell carcinoma (ESCC) patients. Between June 2013 and December 2014, 103 patients with T3-4N0-3M0 thoracic ESCC received esophagectomy, 2FLND with more than 10 lymph nodes removed, and adjuvant RT on a prospective trial. We reviewed the records of patients with T3-4N0-3M0 thoracic ESCC in our institution. One hundred and fifty-seven patients who underwent esophagectomy and 3FLND with more than 15 lymph nodes removed, yet without adjuvant radiation therapy were collected retrospectively. All the patients received postoperative chemotherapy. Propensity score matching (PSM) analysis was used to identify 142 well-balanced patients in the 2FLND + RT group and the 3FLND group for the comparison of both overall survival (OS) and progression free survival (PFS).Kaplan-Meier was used for statistical analysis. After PSM, the 1-year survival rate was 83% for the 2FLND + RT group and 77% for the 3FLND group. The 3-year survival rate was 68% for the 2FLND + RT group and 55% for the 3FLND group. The median OS for all the patients was 56 months (95% Confidence Interval: 20.907-91.093 months), and 41 months (95% Confidence Interval: 3.707-78.293 months) for the 3FLND group, however, the median OS for the 2FLND + RT group was not reached. No significant difference of OS was found between the two groups (P = 0.377). The 1-year PFS and 3-year PFS were 82% and 58% for the 2FLND + RT group, and 75% and 54% for the 3FLND group, respectively. The median PFS for all the patients was 36 months and 39 months for the 3FLND group , however, the median PFS for the 2FLND + RT group was not reached (P = 0.770). For patients with T3-4N0-3M0 thoracic ESCC patients who underwent esophagectomy, 2FLND + RT showed similar effect as 3FLND. Further prospective studies are warranted.